BI has launched a new platform through which it will offer open access to selected preclinical molecules in order to “unlock” the full potential of compounds no longer under development by BI .

https://www.outsourcing-pharma.com/Headlines/Preclinical-Research/Boehringer-Ingelheim-launches-opeme.com-platform